Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells
Open Access
- 3 September 2025
- journal article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 33 (4) , 201047
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- U.S. Department of Veterans Affairs
- National Institutes of Health
- National Cancer Institute (P30CA168524)
This publication has 73 references indexed in Scilit:
- Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell ContentCell, 2010
- Desmoplasia of Pancreatic Ductal AdenocarcinomaClinical Gastroenterology and Hepatology, 2009
- Significance of Increased Apoptosis and Bax Expression in Human Small Intestinal AdenocarcinomaJournal of Histochemistry & Cytochemistry, 2009
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitorsInternational Journal of Pharmaceutics, 2008
- Biodegradation of Aliphatic and Aromatic PolycarbonatesMacromolecular Bioscience, 2007
- Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesisNature Reviews Cancer, 2007
- IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cellsCancer Biology & Therapy, 2007
- Tumor-stroma interactions in pancreatic ductal adenocarcinomaMolecular Cancer Therapeutics, 2007
- A Two-Step Enriched-Nested PCR Technique Enhances Sensitivity for Detection of Codon 12 K-ras Mutations in Pancreatic AdenocarcinomaPancreas, 1997